Brought to you by

Merck, Alnylam end RNAi agreement for ophthalmic drugs
09 Sep 2014
Executive Summary
Merck & Co. and Alnylam Pharmaceuticals (therapeutics based on RNA interference) have signed a multi-year agreement covering the development and marketing of RNAi drugs (particularly VEGF inhibitors) to treat ocular diseases.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com